Inspira Technologies Reports Major Breakthrough in Infection Prevention - Feb 2025 Insights

Here are the key insights extracted from the provided section of the financial report:

1. Company Information:

• Name: Inspira Technologies Oxy B.H.N. Ltd.
• Address: 2 Ha-Tidhar St., Ra’anana 4366504, Israel.

2. Filing Information:

• Type: Form 6-K (Report of Foreign Private Issuer).
• Filing Date: February 11, 2025.
• Commission File Number: 001-40303.
• Report Number: 3 for the month of February 2025.

3. Key Announcement:

• The company issued a press release titled “Inspira Achieves Positive Results of Above 95% For Preventing Bloodstream Infections” on February 11, 2025. This indicates a significant development in their product or technology related to healthcare.

4. Incorporation by Reference:

• Portions of the press release (first, second, fourth, fifth paragraphs, and “Forward-Looking Statements” section) are incorporated by reference into the company’s prior Registration Statements on Form F-3 and Form S-8, indicating a continuation of disclosures and potentially significant updates regarding the company’s offerings.

5. Exhibit:

• The press release is designated as Exhibit 99.1 in the report.

6. Management Signature:

• The report is signed by Dagi Ben-Noon, the Chief Executive Officer, affirming its authenticity and compliance with regulatory requirements.

These insights highlight the company's recent positive developments, regulatory compliance, and the significance of the press release in the context of its ongoing operations and investor communications.